NATIONAL JEWISH HEALTH Patent applications |
Patent application number | Title | Published |
20150087589 | GENES AND PROTEINS ASSOCIATED WITH ANGIOGENESIS AND USES THEREOF - Disclosed is a panel of biomarkers associated with angiogenesis, and the use of such biomarkers (genes, proteins, homologues and analogs thereof) to regulate angiogenesis. Methods for identifying compounds useful for regulating angiogenesis and conditions related thereto are disclosed. | 03-26-2015 |
20150044190 | PRODUCT AND PROCESS FOR LIQUEFACTION OF MUCUS OR SPUTUM - Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system. | 02-12-2015 |
20150010492 | Methods and Compositions for the Disruption of Biofilms - The invention relates to methods of inhibiting biofilm formation or reducing biofilms in a subject or on a device or surface by administering a charged compound such as a polyamino acid to a subject, device or surface. The invention also relates to compositions for inhibiting biofilm formation or reducing biofilms. | 01-08-2015 |
20140220570 | METHODS AND COMPOSITIONS FOR RISK PREDICTION, DIAGNOSIS, PROGNOSIS, AND TREATMENT OF PULMONARY DISORDERS - The invention provides diagnostic and therapeutic targets for pulmonary disease, in particular, fibrotic lung disease. The inventors have found that a genetic variant MUC5B gene is associated with increased expression of the gene, increased risk of developing a pulmonary disease, and an improved prognosis and survival among those developing the pulmonary disease. | 08-07-2014 |
20140206749 | Targeting the Steroidogenic Pathway For Treating and/or Preventing Allergic Diseases - The present invention relates to methods and compositions for treating and/or preventing allergic diseases or conditions by inhibiting one or more components of the steroidogenic pathway. | 07-24-2014 |
20140162357 | METHODS FOR GENERATION OF ANTIBODIES - This invention generally relates to methods for the production of antibody producing cells and antibodies in protooncogene expressing animals. The invention also relates to methods for the efficient production of antibodies specific for antigens that are normally subject to immunological constraints such as self tolerance. The invention further relates to the production of antibody producing cells and antibodies without the need for the conventional fusing of antibody producing B cells with a myeloma fusion partner. | 06-12-2014 |
20140154307 | INHIBITION OF FACTOR B, THE ALTERNATIVE COMPLEMENT PATHWAY AND METHODS RELATED THERETO - Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway. | 06-05-2014 |
20140039063 | LEUKOTRIENES AND ASTHMA EXACERBATION RISK - The invention provides methods for predicting the risk for a subject of exacerbation of an inflammatory disease of the airways upon exposure to an environmental agent as well as methods for reducing a subject's risk of exacerbation of an inflammatory disease of the airways upon exposure to an environmental agent. | 02-06-2014 |
20140005099 | MARKERS FOR DIAGNOSIS OF PULMONARY INFLAMMATION AND METHODS RELATED THERETO | 01-02-2014 |
20130259898 | Vaccine Composition - Disclosed are compositions and the use of the compositions for protection against pathogens comprising an isolated internal pathogenic protein, a TLR agonist and an aluminum salt. | 10-03-2013 |
20130224200 | Product and Process for Inhibition of Biofilm Development - Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing biofilms a compound or formulation that inhibits the formation or polymerization of actin microfilaments or depolymerizes actin microfilaments at or proximal to the site of biofilm formation. Such a compound can be administered in combination with a compound or formulation that inhibits the accumulation or activity of cells that are likely to undergo necrosis at or proximal to the site of biofilm formation (i.e., neutrophils). The methods and compositions can further include the use of anti-DNA and/or anti-mucin compounds, as well as other therapeutic compounds and compositions. | 08-29-2013 |
20130217654 | Surfactant Lipids, Compositions Thereof, and Uses Thereof - The invention generally relates to methods to inhibit inflammation or pathogen infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention further relates to compositions comprising randomly mixed surfactant lipids and methods to produce the compositions. | 08-22-2013 |
20130209432 | PRODUCT AND PROCESS FOR LIQUEFACTION OF MUCUS OR SPUTUM - Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system. | 08-15-2013 |
20130157267 | Marker for Cancer Prognosis and Methods Related Thereto - The present invention is related to the novel discovery that HIF-2α, but not HIF-1 a, selectively regulates adenosine A | 06-20-2013 |
20120301482 | METHODS AND COMPOSITIONS FOR TREATMENT OF LUNG INJURY - The present invention provides a method to treat a condition related to injury of lung epithelial cells in a subject by administering a compound that binds FgfR2b, for example to promote proliferation of lung epithelial stem cells, as well as such compounds in pharmaceutical formulations. The invention also provides for methods to treat a condition related to injury of lung epithelial cells by isolating cells expressing FgfR2b, multiplying the cells and introducing the multiplied cells for repair of lung injury. Related methods for detecting lung injury by detecting the level of expression of FgfR2b well as for treating a condition related to proliferation of lung epithelial cells by administering a compound that binds to FgfR2b, to block receptor signaling are also provided. | 11-29-2012 |
20120283188 | GENES AND PROTEINS ASSOCIATED WITH ANGIOGENESIS AND USES THEREOF - Disclosed is a panel of biomarkers associated with angiogenesis, and the use of such biomarkers (genes, proteins, homologues and analogs thereof) to regulate angiogenesis. Methods for identifying compounds useful for regulating angiogenesis and conditions related thereto are disclosed. | 11-08-2012 |
20120214780 | SUBSTITUTED PORPHYRINS - The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods. | 08-23-2012 |
20120214233 | CYSTATIN C AS AN ANTAGONIST OF TGF-BETA AND METHODS RELATED THERETO - Disclosed are Cystatin C (CysC) homologues, including CystC homologues that act as antagonists or inhibitors of transforming growth factor-β (TGF-β). Also disclosed are methods to identify CystC homologues that are antagonists or inhibitors of TGF-β and compositions and therapeutic methods using CystC and homologues thereof to regulate the activity of TGF-β, and TGF-β-mediated tumor malignancy and invasion and other TGF-β-mediated fibrotic or proliferative conditions and diseases. | 08-23-2012 |
20120149595 | MARKERS FOR DIAGNOSIS OF PULMONARY INFLAMMATION AND METHODS RELATED THERETO - The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA 112, CSPG2, TLR2, and CD163. | 06-14-2012 |
20120148566 | PRODUCT AND METHOD FOR TREATMENT OF CONDITIONS ASSOCIATED WITH RECEPTOR-DESENSITIZATION - Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods. | 06-14-2012 |
20120128759 | METHOD TO INHIBIT AIRWAY HYPERRESPONSIVENESS USING AEROSOLIZED T CELL RECEPTOR ANTIBODIES - Disclosed is a method to reduce airway hyperresponsivesness in an animal by the direct delivery to the lungs of aerosolized antibodies against T cell receptors. The method is particularly useful for treating airway hyperresponsiveness associated with allergic inflammation, is effective at extremely low doses of antibody, and does not have a substantial effect on the peripheral immune system. | 05-24-2012 |
20120114663 | METHODS TO TREAT ALLERGIC CONDITIONS - Disclosed are methods to treat allergic conditions, including pulmonary and non-pulmonary conditions, in a subject by administering a composition that inhibits Pim kinase. Also disclosed are methods to treat allergic conditions in a subject by administering a composition that induces expression of Runx3. | 05-10-2012 |
20120065611 | DISPOSABLE VIAL HOLDER AND METHOD TO PREVENT NEEDLE STICK INJURIES - A vial holder is provided to protect a user's hand from needle sticks. The holder includes a handle and a shield attached to a distal end of the handle. An opening is formed in the distal end of the handle to receive a vial. The vial is placed through the opening and into a passageway of the handle with the upper end of the vial exposed. A user grasps the handle which holds the vial in a stabilized manner. A needle may then safely approach the vial in which inadvertent slippage or movement of the needle results in contact with the needle against the shield and not contact with the user's hand. | 03-15-2012 |
20110250600 | MARKER FOR CANCER PROGNOSIS AND METHODS RELATED THERETO - The present invention is related to the novel discovery that HIF-2α, but not HIF-1α, selectively regulates adenosine A | 10-13-2011 |
20110230974 | AIRWAY ANCHOR SUTURE TO PREVENT AIRWAY STENT MIGRATION - An airway stent with an integral suture anchor is used to prevent migration of the stent within the airway. The suture anchor is incorporated by percutaneous placement of a suture through the neck and into the stent. The distal end of the suture includes an anchor element to secure the suture to the stent. The opposite end of the suture is tensioned and held in place by a suture clamp and a pledget routed over the stent and placed against the neck. Airway stents such as tracheal stents are effective at maintaining airway patency however; a common complication is stent migration. The integral suture anchor provides a reliable, economical, and non-intrusive solution to stent migration. | 09-22-2011 |
20110136775 | Methods for Treating Injury Associated with Exposure to an Alkylating Species - Compounds may be administered to prevent or rescue organ injury following exposure to alkylating agents, such as sulfur mustards. The compounds may be substituted metalloporphyrins. | 06-09-2011 |
20110097327 | PRODUCT AND METHOD FOR TREATMENT OF CONDITIONS ASSOCIATED WITH RECEPTOR-DESENSITIZATION - Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods. | 04-28-2011 |
20100267644 | Cystatin C as an Antagonist of TGF-BETA and Methods Related Thereto - Disclosed are Cystatin C (CysC) homologues, including CystC homologues that act as antagonists or inhibitors of transforming growth factor-β (TGF-β). Also disclosed are methods to identify CystC homologues that are antagonists or inhibitors of TGF-β and compositions and therapeutic methods using CystC and homologues thereof to regulate the activity of TGF-β, and TGF-β-mediated tumor malignancy and invasion and other TGF-β-mediated fibrotic or proliferative conditions and diseases. | 10-21-2010 |
20100196376 | METHOD FOR REDUCING ALLERGEN-INDUCED AIRWAY HYPERRESPONSIVENESS - Disclosed is a method to reduce airway hyperresponsiveness, such as allergen-induced airway hyperresponsiveness, in a mammal by administering an agent that increases the biological activity of a CGRP receptor. Also disclosed are methods for identifying compounds useful in the present method. | 08-05-2010 |
20090311231 | PRODUCT AND PROCESS FOR LIQUEFACTION OF MUCUS OR SPUTUM - Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system. | 12-17-2009 |